{
    "abstract": "Background: An adjuvanted herpes zoster (HZ) subunit vaccine, HZ/su, demonstrated high efficacy against HZ and postherpetic neuralgia (PHN) in two randomized, observer-blind, placebo-controlled trials in adults aged \u226550 and \u226570 years (ZOE-50 and ZOE-70, respectively). Methods: Data from ZOE-50 and ZOE-70 trials were analyzed to evaluate the efficacy of HZ/su against mortality, hospitalizations, and non-PHN complications of HZ including HZ-associated vasculitis, stroke, and disseminated, ophthalmic, neurologic, and visceral diseases. Results: In the pooled ZOE-50/ZOE-70 analysis, 1 of 32 HZ/su recipients (3.1%) and 16 of 477 placebo recipients (3.4%) with a confirmed HZ episode had complications other than PHN. Efficacy against HZ-related complications was 93.7% (95% confidence interval, 59.5\u201399.9%) in adults aged \u226550 years and 91.6% (43.3\u201399.8%) in adults \u226570 years. Five HZ-related hospitalizations, all in placebo recipients, and no HZ-related deaths were reported. Conclusions: HZ/su reduces the risk of HZ-associated complications in older adults (NCT01165177; NCT01165229).",
    "bib_entries": {
        "b0005": {
            "authors": [
                {
                    "first": "Jeffrey I.",
                    "initial": "J.I.",
                    "last": "Cohen"
                }
            ],
            "doi": "10.1056/NEJMcp1302674",
            "firstpage": "255",
            "issn": "00284793",
            "lastpage": "263",
            "pmid": "23863052",
            "pub_year": 2013,
            "title": "Herpes Zoster",
            "volume": "369"
        },
        "b0010": {
            "authors": [
                {
                    "first": "Robert W.",
                    "initial": "R.W.",
                    "last": "Johnson"
                },
                {
                    "first": "Andrew S.C.",
                    "initial": "A.S.C.",
                    "last": "Rice"
                }
            ],
            "doi": "10.1056/NEJMcp1403062",
            "firstpage": "1526",
            "issn": "00284793",
            "lastpage": "1533",
            "pmid": "25317872",
            "pub_year": 2014,
            "title": "Postherpetic neuralgia",
            "volume": "371"
        },
        "b0015": {
            "authors": [
                {
                    "first": "Robert W.",
                    "initial": "R.W.",
                    "last": "Johnson"
                }
            ],
            "doi": "10.1586/erv.10.30",
            "firstpage": "21",
            "issn": "14760584",
            "lastpage": "26",
            "pmid": "20192714",
            "pub_year": 2010,
            "title": "Herpes zoster and postherpetica neuralgia",
            "volume": "9"
        },
        "b0020": {
            "authors": [
                {
                    "first": "Kosuke",
                    "initial": "K.",
                    "last": "Kawai"
                },
                {
                    "first": "Berhanu G.",
                    "initial": "B.G.",
                    "last": "Gebremeskel"
                },
                {
                    "first": "Camilo J.",
                    "initial": "C.J.",
                    "last": "Acosta"
                }
            ],
            "doi": "10.1136/bmjopen-2014-004833",
            "issn": "20446055",
            "pmid": "24916088",
            "pub_year": 2014,
            "title": "Systematic review of incidence and complications of herpes zoster: Towards a global perspective",
            "volume": "4"
        },
        "b0025": {
            "authors": [
                {
                    "first": "Barbara P.",
                    "initial": "B.P.",
                    "last": "Yawn"
                },
                {
                    "first": "Peter C.",
                    "initial": "P.C.",
                    "last": "Wollan"
                },
                {
                    "first": "Maria A.",
                    "initial": "M.A.",
                    "last": "Nagel"
                },
                {
                    "first": "Don",
                    "initial": "D.",
                    "last": "Gilden"
                }
            ],
            "doi": "10.1016/j.mayocp.2015.09.015",
            "firstpage": "33",
            "issn": "00256196",
            "lastpage": "44",
            "pmid": "26704438",
            "pub_year": 2016,
            "title": "Risk of Stroke and Myocardial Infarction after Herpes Zoster in Older Adults in a US Community Population",
            "volume": "91"
        },
        "b0030": {
            "authors": [
                {
                    "first": "Antonio",
                    "initial": "A.",
                    "last": "Volpi"
                }
            ],
            "issn": "09697667",
            "pmid": "17939894",
            "pub_year": 2007,
            "title": "Severe complications of herpes zoster",
            "volume": "14"
        },
        "b0035": {
            "authors": [
                {
                    "first": "Ivan",
                    "initial": "I.",
                    "last": "Vrcek"
                },
                {
                    "first": "Eileen",
                    "initial": "E.",
                    "last": "Choudhury"
                },
                {
                    "first": "Vikram",
                    "initial": "V.",
                    "last": "Durairaj"
                }
            ],
            "doi": "10.1016/j.amjmed.2016.08.039",
            "firstpage": "21",
            "issn": "00029343",
            "lastpage": "26",
            "pmid": "27644149",
            "pub_year": 2017,
            "title": "Herpes Zoster Ophthalmicus: A Review for the Internist",
            "volume": "130"
        },
        "b0040": {
            "authors": [
                {
                    "first": "Barbara P.",
                    "initial": "B.P.",
                    "last": "Yawn"
                },
                {
                    "first": "Peter C.",
                    "initial": "P.C.",
                    "last": "Wollan"
                },
                {
                    "first": "Jennifer L.",
                    "initial": "J.L.",
                    "last": "St. Sauver"
                },
                {
                    "first": "Linda C.",
                    "initial": "L.C.",
                    "last": "Butterfield"
                }
            ],
            "doi": "10.1016/j.mayocp.2013.03.014",
            "firstpage": "562",
            "issn": "00256196",
            "lastpage": "570",
            "pub_year": 2013,
            "title": "Herpes zoster eye complications: Rates and trends",
            "volume": "88"
        },
        "b0045": {
            "authors": [
                {
                    "first": "Himal",
                    "initial": "H.",
                    "last": "Lal"
                },
                {
                    "first": "Anthony L.",
                    "initial": "A.L.",
                    "last": "Cunningham"
                },
                {
                    "first": "Olivier",
                    "initial": "O.",
                    "last": "Godeaux"
                },
                {
                    "first": "Roman",
                    "initial": "R.",
                    "last": "Chlibek"
                },
                {
                    "first": "Javier",
                    "initial": "J.",
                    "last": "Diez-Domingo"
                },
                {
                    "first": "Shinn Jang",
                    "initial": "S.J.",
                    "last": "Hwang"
                },
                {
                    "first": "Myron J.",
                    "initial": "M.J.",
                    "last": "Levin"
                },
                {
                    "first": "Janet E.",
                    "initial": "J.E.",
                    "last": "McElhaney"
                },
                {
                    "first": "Airi",
                    "initial": "A.",
                    "last": "Poder"
                },
                {
                    "first": "Joan",
                    "initial": "J.",
                    "last": "Puig-Barber\u00e0"
                },
                {
                    "first": "Timo",
                    "initial": "T.",
                    "last": "Vesikari"
                },
                {
                    "first": "Daisuke",
                    "initial": "D.",
                    "last": "Watanabe"
                },
                {
                    "first": "Lily",
                    "initial": "L.",
                    "last": "Weckx"
                },
                {
                    "first": "Toufik",
                    "initial": "T.",
                    "last": "Zahaf"
                },
                {
                    "first": "Thomas C.",
                    "initial": "T.C.",
                    "last": "Heineman"
                },
                {
                    "first": null,
                    "initial": null,
                    "last": null
                }
            ],
            "doi": "10.1056/NEJMoa1501184",
            "firstpage": "2087",
            "issn": "00284793",
            "lastpage": "2096",
            "pmid": "25916341",
            "pub_year": 2015,
            "title": "Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults",
            "volume": "372"
        },
        "b0050": {
            "authors": [
                {
                    "first": "A. L.",
                    "initial": "A.L.",
                    "last": "Cunningham"
                },
                {
                    "first": "H.",
                    "initial": "H.",
                    "last": "Lal"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Kovac"
                },
                {
                    "first": "R.",
                    "initial": "R.",
                    "last": "Chlibek"
                },
                {
                    "first": "S. J.",
                    "initial": "S.J.",
                    "last": "Hwang"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "D\u00edez-Domingo"
                },
                {
                    "first": "O.",
                    "initial": "O.",
                    "last": "Godeaux"
                },
                {
                    "first": "M. J.",
                    "initial": "M.J.",
                    "last": "Levin"
                },
                {
                    "first": "J. E.",
                    "initial": "J.E.",
                    "last": "McElhaney"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Puig-Barber\u00e0"
                },
                {
                    "first": "C.",
                    "initial": "C.",
                    "last": "Vanden Abeele"
                },
                {
                    "first": "T.",
                    "initial": "T.",
                    "last": "Vesikari"
                },
                {
                    "first": "D.",
                    "initial": "D.",
                    "last": "Watanabe"
                },
                {
                    "first": "T.",
                    "initial": "T.",
                    "last": "Zahaf"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Ahonen"
                },
                {
                    "first": "E.",
                    "initial": "E.",
                    "last": "Athan"
                },
                {
                    "first": "J. F.",
                    "initial": "J.F.",
                    "last": "Barba-Gomez"
                },
                {
                    "first": "L.",
                    "initial": "L.",
                    "last": "Campora"
                },
                {
                    "first": "F.",
                    "initial": "F.",
                    "last": "De Looze"
                },
                {
                    "first": "H. J.",
                    "initial": "H.J.",
                    "last": "Downey"
                },
                {
                    "first": "W.",
                    "initial": "W.",
                    "last": "Ghesquiere"
                },
                {
                    "first": "I.",
                    "initial": "I.",
                    "last": "Gorfinkel"
                },
                {
                    "first": "T.",
                    "initial": "T.",
                    "last": "Korhonen"
                },
                {
                    "first": "E.",
                    "initial": "E.",
                    "last": "Leung"
                },
                {
                    "first": "S. A.",
                    "initial": "S.A.",
                    "last": "McNeil"
                },
                {
                    "first": "L.",
                    "initial": "L.",
                    "last": "Oostvogels"
                },
                {
                    "first": "L.",
                    "initial": "L.",
                    "last": "Rombo"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Smetana"
                },
                {
                    "first": "L.",
                    "initial": "L.",
                    "last": "Weckx"
                },
                {
                    "first": "W.",
                    "initial": "W.",
                    "last": "Yeo"
                },
                {
                    "first": "T. C.",
                    "initial": "T.C.",
                    "last": "Heineman"
                }
            ],
            "doi": "10.1056/NEJMoa1603800",
            "firstpage": "1019",
            "issn": "00284793",
            "lastpage": "1032",
            "pmid": "27626517",
            "pub_year": 2016,
            "title": "Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older",
            "volume": "375"
        },
        "b0055": {
            "authors": [
                {
                    "first": "Paul M.",
                    "initial": "P.M.",
                    "last": "Coplan"
                },
                {
                    "first": "Kenneth",
                    "initial": "K.",
                    "last": "Schmader"
                },
                {
                    "first": "Alexander",
                    "initial": "A.",
                    "last": "Nikas"
                },
                {
                    "first": "Ivan S.F.",
                    "initial": "I.S.F.",
                    "last": "Chan"
                },
                {
                    "first": "Peter",
                    "initial": "P.",
                    "last": "Choo"
                },
                {
                    "first": "Myron J.",
                    "initial": "M.J.",
                    "last": "Levin"
                },
                {
                    "first": "Gary",
                    "initial": "G.",
                    "last": "Johnson"
                },
                {
                    "first": "Mark",
                    "initial": "M.",
                    "last": "Bauer"
                },
                {
                    "first": "Heather M.",
                    "initial": "H.M.",
                    "last": "Williams"
                },
                {
                    "first": "Karen M.",
                    "initial": "K.M.",
                    "last": "Kaplan"
                },
                {
                    "first": "Harry A.",
                    "initial": "H.A.",
                    "last": "Guess"
                },
                {
                    "first": "Michael N.",
                    "initial": "M.N.",
                    "last": "Oxman"
                }
            ],
            "doi": "10.1016/j.jpain.2004.06.001",
            "firstpage": "344",
            "issn": "15265900",
            "lastpage": "356",
            "pmid": "15336639",
            "pub_year": 2004,
            "title": "Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: Adaptation of the brief pain inventory",
            "volume": "5"
        },
        "b0060": {
            "authors": [
                {
                    "first": "Olli",
                    "initial": "O.",
                    "last": "Miettinen"
                },
                {
                    "first": "Markku",
                    "initial": "M.",
                    "last": "Nurminen"
                }
            ],
            "doi": "10.1002/sim.4780040211",
            "firstpage": "213",
            "issn": "02776715",
            "lastpage": "226",
            "pmid": "4023479",
            "pub_year": 1985,
            "title": "Comparative analysis of two rates",
            "volume": "4"
        },
        "b0065": null,
        "b0070": {
            "authors": [
                {
                    "first": "M. N.",
                    "initial": "M.N.",
                    "last": "Oxman"
                },
                {
                    "first": "M. J.",
                    "initial": "M.J.",
                    "last": "Levin"
                },
                {
                    "first": "G. R.",
                    "initial": "G.R.",
                    "last": "Johnson"
                },
                {
                    "first": "K. E.",
                    "initial": "K.E.",
                    "last": "Schmader"
                },
                {
                    "first": "S. E.",
                    "initial": "S.E.",
                    "last": "Straus"
                },
                {
                    "first": "L. D.",
                    "initial": "L.D.",
                    "last": "Gelb"
                },
                {
                    "first": "R. D.",
                    "initial": "R.D.",
                    "last": "Arbeit"
                },
                {
                    "first": "M. S.",
                    "initial": "M.S.",
                    "last": "Simberkoff"
                },
                {
                    "first": "A. A.",
                    "initial": "A.A.",
                    "last": "Gershon"
                },
                {
                    "first": "L. E.",
                    "initial": "L.E.",
                    "last": "Davis"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Weinberg"
                },
                {
                    "first": "K. D.",
                    "initial": "K.D.",
                    "last": "Boardman"
                },
                {
                    "first": "H. M.",
                    "initial": "H.M.",
                    "last": "Williams"
                },
                {
                    "first": "J. Hongyuan",
                    "initial": "J.H.",
                    "last": "Zhang"
                },
                {
                    "first": "P. N.",
                    "initial": "P.N.",
                    "last": "Peduzzi"
                },
                {
                    "first": "C. E.",
                    "initial": "C.E.",
                    "last": "Beisel"
                },
                {
                    "first": "V. A.",
                    "initial": "V.A.",
                    "last": "Morrison"
                },
                {
                    "first": "J. C.",
                    "initial": "J.C.",
                    "last": "Guatelli"
                },
                {
                    "first": "P. A.",
                    "initial": "P.A.",
                    "last": "Brooks"
                },
                {
                    "first": "C. A.",
                    "initial": "C.A.",
                    "last": "Kauffman"
                },
                {
                    "first": "C. T.",
                    "initial": "C.T.",
                    "last": "Pachucki"
                },
                {
                    "first": "K. M.",
                    "initial": "K.M.",
                    "last": "Neuzil"
                },
                {
                    "first": "R. F.",
                    "initial": "R.F.",
                    "last": "Betts"
                },
                {
                    "first": "P. F.",
                    "initial": "P.F.",
                    "last": "Wright"
                },
                {
                    "first": "M. R.",
                    "initial": "M.R.",
                    "last": "Griffin"
                },
                {
                    "first": "P.",
                    "initial": "P.",
                    "last": "Brunell"
                },
                {
                    "first": "N. E.",
                    "initial": "N.E.",
                    "last": "Soto"
                },
                {
                    "first": "A. R.",
                    "initial": "A.R.",
                    "last": "Marques"
                },
                {
                    "first": "S. K.",
                    "initial": "S.K.",
                    "last": "Keay"
                },
                {
                    "first": "R. P.",
                    "initial": "R.P.",
                    "last": "Goodman"
                },
                {
                    "first": "D. J.",
                    "initial": "D.J.",
                    "last": "Cotton"
                },
                {
                    "first": "J. W.",
                    "initial": "J.W.",
                    "last": "Gnann"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Loutit"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Holodniy"
                },
                {
                    "first": "W. A.",
                    "initial": "W.A.",
                    "last": "Keitel"
                },
                {
                    "first": "G. E.",
                    "initial": "G.E.",
                    "last": "Crawford"
                },
                {
                    "first": "S. S.",
                    "initial": "S.S.",
                    "last": "Yeh"
                },
                {
                    "first": "Z.",
                    "initial": "Z.",
                    "last": "Lobo"
                },
                {
                    "first": "J. F.",
                    "initial": "J.F.",
                    "last": "Toney"
                },
                {
                    "first": "R. N.",
                    "initial": "R.N.",
                    "last": "Greenberg"
                },
                {
                    "first": "P. M.",
                    "initial": "P.M.",
                    "last": "Keller"
                },
                {
                    "first": "R.",
                    "initial": "R.",
                    "last": "Harbecke"
                },
                {
                    "first": "A. R.",
                    "initial": "A.R.",
                    "last": "Hayward"
                },
                {
                    "first": "M. R.",
                    "initial": "M.R.",
                    "last": "Irwin"
                },
                {
                    "first": "T. C.",
                    "initial": "T.C.",
                    "last": "Kyriakides"
                },
                {
                    "first": "C. Y.",
                    "initial": "C.Y.",
                    "last": "Chan"
                },
                {
                    "first": "I. S.F.",
                    "initial": "I.S.F.",
                    "last": "Chan"
                },
                {
                    "first": "W. W.B.",
                    "initial": "W.W.B.",
                    "last": "Wang"
                },
                {
                    "first": "P. W.",
                    "initial": "P.W.",
                    "last": "Annunziato"
                },
                {
                    "first": "J. L.",
                    "initial": "J.L.",
                    "last": "Silber"
                }
            ],
            "doi": "10.1056/NEJMoa051016",
            "firstpage": "2271",
            "issn": "00284793",
            "lastpage": "2365",
            "pmid": "15930418",
            "pub_year": 2005,
            "title": "A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults",
            "volume": "352"
        }
    },
    "body_text": [
        {
            "endOffset": 16713,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "All statistical analyses were performed using SAS version 9.3 (SAS Institute) and StatXact 9.0 (Cytel) procedure for SAS.",
            "startOffset": 16592,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 12497,
            "parents": [],
            "refoffsets": {
                "b0005": {
                    "endOffset": 12496,
                    "startOffset": 12489
                },
                "b0020": {
                    "endOffset": 12496,
                    "startOffset": 12489
                },
                "b0025": {
                    "endOffset": 12496,
                    "startOffset": 12489
                },
                "b0030": {
                    "endOffset": 12496,
                    "startOffset": 12489
                }
            },
            "secId": "s0005",
            "sentence": "Other HZ complications include disseminated HZ, and neurological, visceral, or vascular diseases, including stroke [1,4\u20136].",
            "startOffset": 12374,
            "title": "Introduction"
        },
        {
            "endOffset": 21189,
            "parents": [],
            "secId": "s0065",
            "sentence": "The large cohort of placebo recipients in these trials provided robust estimates of the incidence of HZ complications, without the biases inherent in population-based estimates from databases and case series.",
            "startOffset": 20981,
            "title": "Discussion"
        },
        {
            "endOffset": 23553,
            "parents": [],
            "secId": "s0075",
            "sentence": "TH is a consultant for GSK and is the co-inventor of a patent application related to the vaccine used in this study.",
            "startOffset": 23437,
            "title": "Conflicts of interest"
        },
        {
            "endOffset": 24271,
            "parents": [],
            "secId": "s0075",
            "sentence": "AV received honoraria for the participation to an advisory board for Sanofi Pasteur MSD and an adjudication committee for Watermark.",
            "startOffset": 24139,
            "title": "Conflicts of interest"
        },
        {
            "endOffset": 12154,
            "parents": [],
            "refoffsets": {
                "b0005": {
                    "endOffset": 12153,
                    "startOffset": 12148
                },
                "b0010": {
                    "endOffset": 12153,
                    "startOffset": 12148
                }
            },
            "secId": "s0005",
            "sentence": "Herpes zoster (HZ) results from the reactivation of latent varicella-zoster virus (VZV) in sensory ganglia, typically years after primary infection [1,2].",
            "startOffset": 12000,
            "title": "Introduction"
        },
        {
            "endOffset": 21291,
            "parents": [],
            "secId": "s0065",
            "sentence": "Excluding PHN, the overall complication rate for placebo recipients \u226550 years was low at 0.3/1000 PY.",
            "startOffset": 21190,
            "title": "Discussion"
        },
        {
            "endOffset": 13671,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Adults aged \u226550 years (ZOE-50) or \u226570 years (ZOE-70) received two doses of HZ/su (Shingrix, GSK) or placebo intramuscularly at months 0 and 2.",
            "startOffset": 13529,
            "title": "Study design and participants"
        },
        {
            "endOffset": 13528,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0045": {
                    "endOffset": 13527,
                    "startOffset": 13521
                },
                "b0050": {
                    "endOffset": 13527,
                    "startOffset": 13521
                }
            },
            "secId": "s0015",
            "sentence": "ZOE-50 (Clinicaltrials.gov, NCT01165177) and ZOE-70 (NCT01165229) were randomized, observer-blind, placebo-controlled, phase 3 studies conducted concurrently in 18 countries in Europe, North America, Latin America, and Asia-Australia [9,10].",
            "startOffset": 13287,
            "title": "Study design and participants"
        },
        {
            "endOffset": 18297,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "No cases of HZ-associated visceral disease or stroke were reported in participants in either the HZ/su group or placebo group.",
            "startOffset": 18171,
            "title": "HZ/su efficacy against HZ-related complications other than PHN"
        },
        {
            "endOffset": 15948,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Vaccine efficacy was defined as 1 minus the rate ratio.",
            "startOffset": 15893,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 18597,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "Excluding PHN, the HZ complication rate for placebo recipients \u226550 years was 0.3/1000 person-years (PY) overall and increased with age (Table 3).",
            "startOffset": 18452,
            "title": "HZ/su efficacy against HZ-related complications other than PHN"
        },
        {
            "endOffset": 23736,
            "parents": [],
            "secId": "s0075",
            "sentence": "AC received honoraria paid to his institution from GSK, Merck, and Sequirus.",
            "startOffset": 23660,
            "title": "Conflicts of interest"
        },
        {
            "endOffset": 20689,
            "parents": [],
            "secId": "s0065",
            "sentence": "Because the number of breakthrough HZ cases in the HZ/su vaccinated group was small, even in the pooled population, it is not possible to determine whether HZ/su prevented complications in vaccine recipients with breakthrough HZ.",
            "startOffset": 20460,
            "title": "Discussion"
        },
        {
            "endOffset": 13749,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0045": {
                    "endOffset": 13748,
                    "startOffset": 13742
                },
                "b0050": {
                    "endOffset": 13748,
                    "startOffset": 13742
                }
            },
            "secId": "s0015",
            "sentence": "The design and results of both studies have been previously published [9,10].",
            "startOffset": 13672,
            "title": "Study design and participants"
        },
        {
            "endOffset": 18452,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "All participants with HZ-related complications received antiviral therapy (usually within the first 3 days after onset) and most received pain medication.",
            "startOffset": 18298,
            "title": "HZ/su efficacy against HZ-related complications other than PHN"
        },
        {
            "endOffset": 21552,
            "parents": [],
            "secId": "s0065",
            "sentence": "When PHN was included as a complication, the complication rate was 11%.",
            "startOffset": 21481,
            "title": "Discussion"
        },
        {
            "endOffset": 21815,
            "parents": [],
            "secId": "s0065",
            "sentence": "This may be partly attributable to the enrolment of only immunocompetent individuals into our trials.",
            "startOffset": 21714,
            "title": "Discussion"
        },
        {
            "endOffset": 24138,
            "parents": [],
            "secId": "s0075",
            "sentence": "ML received grants from GSK and Merck Sharp & Dohme, participated to advisory boards sponsored by GSK and Merck Sharp & Dohme, and received royalties for a zoster vaccine patent owned by Merck Sharp & Dohme.",
            "startOffset": 23931,
            "title": "Conflicts of interest"
        },
        {
            "endOffset": 22820,
            "parents": [],
            "secId": "s0070",
            "sentence": "LC contributed to the data analysis, data interpretation, and writing of the manuscript.",
            "startOffset": 22732,
            "title": "Contributions"
        },
        {
            "endOffset": 15083,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0045": {
                    "endOffset": 14946,
                    "startOffset": 14940
                },
                "b0050": {
                    "endOffset": 14946,
                    "startOffset": 14940
                }
            },
            "secId": "s0035",
            "sentence": "All analyses were performed in the modified vaccinated cohort [9,10], which excluded participants who did not receive the second dose or who had a confirmed HZ episode within 30 days after the second dose.",
            "startOffset": 14878,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 12825,
            "parents": [],
            "refoffsets": {
                "b0020": {
                    "endOffset": 12824,
                    "startOffset": 12819
                },
                "b0040": {
                    "endOffset": 12824,
                    "startOffset": 12819
                }
            },
            "secId": "s0005",
            "sentence": "The risk of HZ ophthalmicus among HZ patients ranges between 10% and 15%, with ophthalmic disease in approximately 30\u201380% of these cases [4,8].",
            "startOffset": 12682,
            "title": "Introduction"
        },
        {
            "endOffset": 12681,
            "parents": [],
            "refoffsets": {
                "b0035": {
                    "endOffset": 12680,
                    "startOffset": 12677
                }
            },
            "secId": "s0005",
            "sentence": "HZ ophthalmicus occurs when VZV reactivation affects the ophthalmic branch of the fifth cranial nerve and can involve eye structures (hereafter referred to as ophthalmic disease) [7].",
            "startOffset": 12498,
            "title": "Introduction"
        },
        {
            "endOffset": 14855,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "In the analysis, these events were considered complications of HZ only if they were associated with a confirmed HZ case.",
            "startOffset": 14735,
            "title": "Herpes zoster complications"
        },
        {
            "endOffset": 18804,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "HZ/su reduced the risk of HZ-related complications other than PHN by 93.7% (95% CI, 59.5\u201399.9%; P = 0.0003) in participants \u226550 years and by 91.6% (95% CI, 43.3\u201399.8%; P = 0.0035) in participants \u226570 years.",
            "startOffset": 18598,
            "title": "HZ/su efficacy against HZ-related complications other than PHN"
        },
        {
            "endOffset": 16591,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "P-values of \u22640.05 were considered to indicate statistical significance.",
            "startOffset": 16520,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 13136,
            "parents": [],
            "refoffsets": {
                "b0045": {
                    "endOffset": 13135,
                    "startOffset": 13129
                },
                "b0050": {
                    "endOffset": 13135,
                    "startOffset": 13129
                }
            },
            "secId": "s0005",
            "sentence": "In two phase 3 clinical trials, a HZ subunit vaccine (HZ/su), containing recombinant VZV glycoprotein E and the AS01B Adjuvant System, was highly efficacious in preventing HZ and PHN in older adults [9,10].",
            "startOffset": 12930,
            "title": "Introduction"
        },
        {
            "endOffset": 22057,
            "parents": [],
            "refoffsets": {
                "b0005": {
                    "endOffset": 21985,
                    "startOffset": 21980
                },
                "b0010": {
                    "endOffset": 21985,
                    "startOffset": 21980
                }
            },
            "secId": "s0065",
            "sentence": "In addition, as HZ episodes were closely monitored during the trials, a relatively high proportion of participants with HZ likely received prompt antiviral therapy [1,2], which may have reduced the rate of complications and hospitalizations.",
            "startOffset": 21816,
            "title": "Discussion"
        },
        {
            "endOffset": 22539,
            "parents": [],
            "secId": "s0065",
            "sentence": "In conclusion, our results indicate that vaccination with two doses of HZ/su substantially reduces the overall risk of HZ-associated complications among adults \u226550 years.",
            "startOffset": 22369,
            "title": "Discussion"
        },
        {
            "endOffset": 24448,
            "parents": [],
            "secId": "s0080",
            "sentence": "This work was supported by GlaxoSmithKline Biologicals SA, Belgium, which paid for all costs associated with the development and the publishing of the present manuscript.",
            "startOffset": 24278,
            "title": "Funding"
        },
        {
            "endOffset": 17202,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0045",
            "sentence": "Therefore, during the entire ZOE-50 study period (mean follow-up, 3.9 \u00b1 0.7 years), 263 subjects had a confirmed HZ episode: 9 in the HZ/su group and 254 in the placebo group.",
            "startOffset": 17027,
            "title": "Study population"
        },
        {
            "endOffset": 22731,
            "parents": [],
            "secId": "s0070",
            "sentence": "AC, RJ, ML, and AV contributed to the data collection, data interpretation, and writing of the manuscript.",
            "startOffset": 22625,
            "title": "Contributions"
        },
        {
            "endOffset": 13247,
            "parents": [],
            "secId": "s0005",
            "sentence": "Here, we report the efficacy of HZ/su in preventing HZ-associated complications, hospitalizations, and deaths.",
            "startOffset": 13137,
            "title": "Introduction"
        },
        {
            "endOffset": 13876,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0045": {
                    "endOffset": 13875,
                    "startOffset": 13869
                },
                "b0050": {
                    "endOffset": 13875,
                    "startOffset": 13869
                }
            },
            "secId": "s0020",
            "sentence": "The primary objectives were to assess HZ/su efficacy against HZ (ZOE-50 and ZOE-70) and PHN (ZOE-70) [9,10].",
            "startOffset": 13768,
            "title": "Study objectives"
        },
        {
            "endOffset": 19238,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "HZ/su reduced HZ-related complications including PHN by 91.3% (95% CI, 78.5\u201397.3%; P < 0.0001) in participants \u226550 years and by 88.6% (95% CI, 71.2\u201396.5%; P < 0.0001) in those \u226570 years.",
            "startOffset": 19052,
            "title": "HZ/su efficacy against HZ-related complications including PHN"
        },
        {
            "endOffset": 22225,
            "parents": [],
            "secId": "s0065",
            "sentence": "In the pooled analysis, efficacy against HZ-related complications was similar in adults aged \u226550 years and \u226570 years, indicating that efficacy did not decline with age.",
            "startOffset": 22057,
            "title": "Discussion"
        },
        {
            "endOffset": 15673,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Efficacy against HZ-related mortality and hospitalizations considered the exact inference on the relative risk stratified for age groups and regions, conditionally to the total number of confirmed HZ cases observed and time at risk.",
            "startOffset": 15441,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 20901,
            "parents": [],
            "secId": "s0065",
            "sentence": "Similarly, in the ZOE-70 trial, fewer hospitalizations were seen in the HZ/su group than in the placebo group but the difference was not statistically significant due to the low numbers of events in both groups.",
            "startOffset": 20690,
            "title": "Discussion"
        },
        {
            "endOffset": 12303,
            "parents": [],
            "refoffsets": {
                "b0010": {
                    "endOffset": 12302,
                    "startOffset": 12297
                },
                "b0015": {
                    "endOffset": 12302,
                    "startOffset": 12297
                }
            },
            "secId": "s0005",
            "sentence": "The most common complication of HZ, postherpetic neuralgia (PHN), is a chronic neuropathic pain that persists after resolution of the HZ rash [2,3].",
            "startOffset": 12155,
            "title": "Introduction"
        },
        {
            "endOffset": 19921,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "HZ/su efficacy against HZ-related mortality or hospitalization was 100% (95% CI, \u22129.9\u2013100.0%; P = 0.0636).",
            "startOffset": 19815,
            "title": "Reduction of mortality and hospitalizations related to a confirmed HZ episode"
        },
        {
            "endOffset": 17349,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "refoffsets": {
                "b0050": {
                    "endOffset": 17348,
                    "startOffset": 17344
                }
            },
            "secId": "s0045",
            "sentence": "In ZOE-70 (mean follow-up, 3.7 \u00b1 0.8 years), 246 participants had a confirmed HZ episode: 23 in the HZ/su group and 223 in the placebo group [10].",
            "startOffset": 17203,
            "title": "Study population"
        },
        {
            "endOffset": 15440,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "The analysis was stratified by age group and weighted according to the proportion of participants in each age group.",
            "startOffset": 15324,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 21713,
            "parents": [],
            "refoffsets": {
                "b0020": {
                    "endOffset": 21712,
                    "startOffset": 21703
                },
                "b0065": {
                    "endOffset": 21712,
                    "startOffset": 21703
                },
                "b0070": {
                    "endOffset": 21712,
                    "startOffset": 21703
                }
            },
            "secId": "s0065",
            "sentence": "The age-specific incidence of PHN and other HZ-related complications was less common among placebo recipients in our studies than in previous studies [4,13,14].",
            "startOffset": 21553,
            "title": "Discussion"
        },
        {
            "endOffset": 22368,
            "parents": [],
            "refoffsets": {
                "b0045": {
                    "endOffset": 22367,
                    "startOffset": 22361
                },
                "b0050": {
                    "endOffset": 22367,
                    "startOffset": 22361
                }
            },
            "secId": "s0065",
            "sentence": "This was true whether or not PHN was included in the analysis and consistent with the overall efficacy against HZ previously described [9,10].",
            "startOffset": 22226,
            "title": "Discussion"
        },
        {
            "endOffset": 22987,
            "parents": [],
            "secId": "s0070",
            "sentence": "All authors read and approved the final manuscript.",
            "startOffset": 22936,
            "title": "Contributions"
        },
        {
            "endOffset": 15323,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0060": {
                    "endOffset": 15322,
                    "startOffset": 15318
                }
            },
            "secId": "s0035",
            "sentence": "In both studies, the incidence of HZ-associated complications in participants with confirmed HZ (overall and by age group) was compared between HZ/su and placebo recipients using the asymptotic standardized unconditional binomial test [12].",
            "startOffset": 15083,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 23659,
            "parents": [],
            "secId": "s0075",
            "sentence": "AC and AV declare that their institution received a grant from GSK for the conduct of the clinical trial.",
            "startOffset": 23554,
            "title": "Conflicts of interest"
        },
        {
            "endOffset": 12373,
            "parents": [],
            "refoffsets": {
                "b0020": {
                    "endOffset": 12372,
                    "startOffset": 12369
                }
            },
            "secId": "s0005",
            "sentence": "In adults aged \u226550 years, the risk of developing PHN can be >30% [4].",
            "startOffset": 12304,
            "title": "Introduction"
        },
        {
            "endOffset": 19814,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "These were for neurologic disease (two participants), disseminated HZ (one participant), neurologic and ophthalmic disease (one participant), and reaction to codeine given for HZ pain relief (one participant).",
            "startOffset": 19605,
            "title": "Reduction of mortality and hospitalizations related to a confirmed HZ episode"
        },
        {
            "endOffset": 17733,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "At least one HZ-related complication other than PHN was reported in 16 out of 477 (3.4%) placebo recipients with a confirmed HZ episode.",
            "startOffset": 17597,
            "title": "HZ/su efficacy against HZ-related complications other than PHN"
        },
        {
            "endOffset": 14734,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "The following complications of suspected HZ cases were recorded by the investigators as adverse events or serious adverse events, as appropriate: HZ vasculitis; disseminated HZ; ophthalmic, neurologic, or visceral disease; and stroke (definitions in Table 1).",
            "startOffset": 14475,
            "title": "Herpes zoster complications"
        },
        {
            "endOffset": 23344,
            "parents": [],
            "secId": "s0075",
            "sentence": "MK and HL hold shares or stock options in GSK as part of their current or former employee remuneration.",
            "startOffset": 23241,
            "title": "Conflicts of interest"
        },
        {
            "endOffset": 16480,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Therefore, a post-hoc analysis was performed to assess efficacy in reducing the incidence of HZ-associated complications (exclusive and inclusive of PHN) in the combined ZOE-50/ZOE-70 study population, both for participants aged \u226550 years and \u226570 years.",
            "startOffset": 16227,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 16829,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "refoffsets": {
                "b0045": {
                    "endOffset": 16828,
                    "startOffset": 16822
                },
                "b0050": {
                    "endOffset": 16828,
                    "startOffset": 16822
                }
            },
            "secId": "s0045",
            "sentence": "ZOE-50 and ZOE-70 enrolled 15,411 and 13,900 evaluable participants, respectively [9,10].",
            "startOffset": 16740,
            "title": "Study population"
        },
        {
            "endOffset": 20109,
            "parents": [],
            "secId": "s0065",
            "sentence": "Based on the ZOE-50/ZOE-70 pooled analysis, HZ/su efficacy against HZ-related complications other than PHN was 93.7% in participants aged \u226550 years and 91.6% in those \u226570 years.",
            "startOffset": 19932,
            "title": "Discussion"
        },
        {
            "endOffset": 23240,
            "parents": [],
            "secId": "s0075",
            "sentence": "MK and LC are employees, and TH and HL former employees, of the GSK group of companies (GSK).",
            "startOffset": 23147,
            "title": "Conflicts of interest"
        },
        {
            "endOffset": 23930,
            "parents": [],
            "secId": "s0075",
            "sentence": "RJ received honoraria for consultancy and funding for a meeting he organized from Merck, funding from Sanofi Pasteur MSD to organize a scientific meeting, and honoraria as a consultant for GSK.",
            "startOffset": 23737,
            "title": "Conflicts of interest"
        },
        {
            "endOffset": 14445,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0050": {
                    "endOffset": 14444,
                    "startOffset": 14437
                },
                "b0055": {
                    "endOffset": 14444,
                    "startOffset": 14437
                }
            },
            "secId": "s0025",
            "sentence": "PHN was defined as a \u2018worst pain\u2019 score \u22653 persisting or developing more than 90 days after the onset of HZ rash, based on item #3 of the Zoster Brief Pain Inventory questionnaire [10,11].",
            "startOffset": 14257,
            "title": "Assessment of HZ and PHN cases"
        },
        {
            "endOffset": 15892,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "This method computes an exact confidence interval (CI) around the rate ratio (ratio of the event rates in the HZ/su versus placebo group) and takes into account the follow-up duration of the subjects within each group.",
            "startOffset": 15674,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 12930,
            "parents": [],
            "refoffsets": {
                "b0020": {
                    "endOffset": 12929,
                    "startOffset": 12926
                }
            },
            "secId": "s0005",
            "sentence": "The incidence, severity, and duration of PHN and other HZ complications generally increase with age [4].",
            "startOffset": 12826,
            "title": "Introduction"
        },
        {
            "endOffset": 22935,
            "parents": [],
            "secId": "s0070",
            "sentence": "MK, HL, and TH contributed to the study design, data analysis, data interpretation, and writing of the manuscript.",
            "startOffset": 22821,
            "title": "Contributions"
        },
        {
            "endOffset": 19051,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "In the ZOE-50/ZOE-70 combined population \u226550 years with confirmed HZ, PHN and other complications developed in 5 of 32 HZ/su recipients and in 58 of 477 placebo recipients (Table S1).",
            "startOffset": 18868,
            "title": "HZ/su efficacy against HZ-related complications including PHN"
        },
        {
            "endOffset": 18089,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "One participant had both ophthalmic and neurologic (meningitis) disease.",
            "startOffset": 18017,
            "title": "HZ/su efficacy against HZ-related complications other than PHN"
        },
        {
            "endOffset": 21374,
            "parents": [],
            "secId": "s0065",
            "sentence": "This represents a HZ complication rate of 3% among participants with confirmed HZ.",
            "startOffset": 21292,
            "title": "Discussion"
        },
        {
            "endOffset": 19397,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "In ZOE-50, no deaths or hospitalizations related to a HZ episode were reported.",
            "startOffset": 19318,
            "title": "Reduction of mortality and hospitalizations related to a confirmed HZ episode"
        },
        {
            "endOffset": 17026,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "refoffsets": {
                "b0045": {
                    "endOffset": 16930,
                    "startOffset": 16927
                }
            },
            "secId": "s0045",
            "sentence": "Since publication of the primary results of ZOE-50 (which was ongoing at the time of publication [9]), 47 additional participants had HZ episodes: 3 in the HZ/su group and 44 in the placebo group.",
            "startOffset": 16830,
            "title": "Study population"
        },
        {
            "endOffset": 19604,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "In ZOE-70, no HZ-related deaths or hospitalizations were reported for participants who received HZ/su, whereas five HZ-related hospitalizations were reported in participants who received placebo (Table S2).",
            "startOffset": 19398,
            "title": "Reduction of mortality and hospitalizations related to a confirmed HZ episode"
        },
        {
            "endOffset": 16122,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "HZ/su efficacy against HZ-associated complications or against mortality and hospitalizations was demonstrated if the lower limit of the two-sided 95% CI was greater than 0%.",
            "startOffset": 15949,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 18170,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "Most HZ-related complications occurred in participants \u226570 years (13/17; 76.5%).",
            "startOffset": 18090,
            "title": "HZ/su efficacy against HZ-related complications other than PHN"
        },
        {
            "endOffset": 18016,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "The most frequently reported complication in the placebo group was ophthalmic disease (seven participants [1.5%]), followed by disseminated disease (six participants [1.2%]), neurologic disease (three participants [0.6%]), and one case of vasculitis presumed to be due to HZ (0.2%).",
            "startOffset": 17734,
            "title": "HZ/su efficacy against HZ-related complications other than PHN"
        },
        {
            "endOffset": 20981,
            "parents": [],
            "secId": "s0065",
            "sentence": "However, a limitation of our study is that some of these analyses are post-hoc.",
            "startOffset": 20902,
            "title": "Discussion"
        },
        {
            "endOffset": 20459,
            "parents": [],
            "secId": "s0065",
            "sentence": "This indicates that efficacy against complications other than PHN was largely driven by the prevention of HZ in HZ/su recipients.",
            "startOffset": 20330,
            "title": "Discussion"
        },
        {
            "endOffset": 16519,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "All significance tests were two-tailed.",
            "startOffset": 16480,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 17596,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "In the overall ZOE-50/ZOE-70 combined population, only one HZ-related complication, ophthalmic disease, was observed among the 32 HZ/su recipients (3.1%) with confirmed HZ (Table 2).",
            "startOffset": 17414,
            "title": "HZ/su efficacy against HZ-related complications other than PHN"
        },
        {
            "endOffset": 14078,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "The secondary and exploratory objectives of each study described here included HZ/su efficacy in reducing HZ-associated complications and efficacy in reducing HZ-related mortality and hospitalizations.",
            "startOffset": 13877,
            "title": "Study objectives"
        },
        {
            "endOffset": 16226,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "The low number of confirmed HZ cases in the HZ/su group in each study limited the power of the analyses.",
            "startOffset": 16122,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 14256,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0045": {
                    "endOffset": 14255,
                    "startOffset": 14249
                },
                "b0050": {
                    "endOffset": 14255,
                    "startOffset": 14249
                }
            },
            "secId": "s0025",
            "sentence": "Subject-reported suspected HZ cases were confirmed by polymerase chain reaction or by an ascertainment committee, as previously described [9,10].",
            "startOffset": 14111,
            "title": "Assessment of HZ and PHN cases"
        },
        {
            "endOffset": 22612,
            "parents": [],
            "secId": "s0900",
            "sentence": "Shingrix is a trademark of the GSK group of companies.",
            "startOffset": 22558,
            "title": "Trademark statement"
        },
        {
            "endOffset": 21480,
            "parents": [],
            "secId": "s0065",
            "sentence": "The most common complications were ophthalmic (1.5%), disseminated (1.2%) and neurologic (0.6%) diseases.",
            "startOffset": 21375,
            "title": "Discussion"
        },
        {
            "endOffset": 23126,
            "parents": [],
            "secId": "s0070",
            "sentence": "GSK takes a commitment to convey a message in a way that would be easily understandable by health care professionals (Supplementary text).",
            "startOffset": 22988,
            "title": "Contributions"
        },
        {
            "endOffset": 20329,
            "parents": [],
            "refoffsets": {
                "b0045": {
                    "endOffset": 20251,
                    "startOffset": 20248
                },
                "b0050": {
                    "endOffset": 20328,
                    "startOffset": 20324
                }
            },
            "secId": "s0065",
            "sentence": "These results are consistent with the overall efficacy against HZ, which was 97.2% (95% CI, 93.7\u201399.0%) in adults aged \u226550 years (ZOE-50) [9] and 91.3% (95% CI, 86.8\u201394.5%) in adults aged \u226570 years (ZOE-50/ZOE-70) [10].",
            "startOffset": 20110,
            "title": "Discussion"
        },
        {
            "endOffset": 23436,
            "parents": [],
            "secId": "s0075",
            "sentence": "HL is a current employee of Pfizer and receives stock as part of his employee remuneration.",
            "startOffset": 23345,
            "title": "Conflicts of interest"
        }
    ],
    "docId": "S0264410X18302032",
    "metadata": {
        "asjc": [
            "1313",
            "2400",
            "2725",
            "2739",
            "3400"
        ],
        "authors": [
            {
                "email": "martina.z.kovac@gsk.com",
                "first": "Martina",
                "initial": "M.",
                "last": "Kovac"
            },
            {
                "email": "himallal@yahoo.com",
                "first": "Himal",
                "initial": "H.",
                "last": "Lal"
            },
            {
                "email": "tony.cunningham@sydney.edu.au",
                "first": "Anthony L.",
                "initial": "A.L.",
                "last": "Cunningham"
            },
            {
                "email": "Myron.Levin@ucdenver.edu",
                "first": "Myron J.",
                "initial": "M.J.",
                "last": "Levin"
            },
            {
                "email": "rwjbristol@doctors.org.uk",
                "first": "Robert W.",
                "initial": "R.W.",
                "last": "Johnson"
            },
            {
                "email": "laura.e.campora@gsk.com",
                "first": "Laura",
                "initial": "L.",
                "last": "Campora"
            },
            {
                "email": "volpi@uniroma2.it",
                "first": "Antonio",
                "initial": "A.",
                "last": "Volpi"
            },
            {
                "email": "theineman@halozyme.com",
                "first": "Thomas C.",
                "initial": "T.C.",
                "last": "Heineman"
            },
            {
                "email": null,
                "first": null,
                "initial": null,
                "last": null
            }
        ],
        "doi": "10.1016/j.vaccine.2018.02.029",
        "firstpage": "1537",
        "issn": "0264410X",
        "keywords": [
            "Complications",
            "Herpes zoster",
            "Hospitalisation",
            "Postherpetic neuralgia",
            "Vaccine efficacy",
            "Varicella-zoster virus"
        ],
        "lastpage": "1541",
        "openaccess": "Full",
        "pub_year": 2018,
        "subjareas": [
            "BIOC",
            "IMMU",
            "MEDI",
            "VETE"
        ],
        "title": "Complications of herpes zoster in immunocompetent older adults: Incidence in vaccine and placebo groups in two large phase 3 trials"
    }
}